Journal in Pharmacology // Drug Repurposing

Journal in Pharmacology

Indian Journal of

  • British Journal of Pharmacology features midkine in a special edition with 16 new publications
  • Strong validation of midkine and its role in disease

Cellmid Limited (ASX: CDY) advises that The British Journal of Pharmacology (BJP) has recently published a special edition dedicated to midkine (MK) including 16 research papers by various authors. The BJP is the premier peer-reviewed publication of the British Pharmacological Society, and it is recognised as one of the most influential international journals covering all aspects of experimental pharmacology.

The BJP Midkine Issue contains invited reviews from pre-eminent MK researchers from around the world, with comprehensive up-to-date articles covering the gamut of MK biology. Publications examine the role of MK in diseases including various cancers, kidney diseases, cardiovascular disease, multiple sclerosis and neurodegenerative disorders. New understanding of MK signaling and receptors is also featured. The full table of contents and the articles themselves can be viewed at

“Being featured in a high-impact, internationally regarded journal with a global audience is a strong validation of MK’s importance in health and disease”, said Cellmid CEO, Maria Halasz. “Cellmid recognised this potential early on, and it is pleasing to see the increasing and ever wider realisation of MK’s potential utility as a disease target or as a therapeutic agent in its own right.”

“Having MK reviewed in this way is very helpful to Cellmid’s product development programs”, added Darren Jones, Head of Product Development. “Publications such as these provide strong supporting evidence to regulators, key opinion leaders and potential biotech and pharma partners. They provide a solid foundation upon which Cellmid can build its clinical programs and collaborations.”

Since its discovery in 1988, MK has been the subject of over 670 peer-review papers.

About Cellmid Limited (ASX: CDY)
Cellmid is an Australian biotechnology company with lead drug candidates in immunooncology. The Company is developing innovative novel therapies and diagnostic...

You might also like

Here's an interesting one.

by Barcelo

I read through it real quick and it seems to make a good argument for both sides. This is an older article (1994), but this is the time when psychopharmacological drugs were being improved and it was still commonly accepted that psychotropic drugs were harmful or unnecessary.
The title is, 'The family therapist's guide to psychopharmacology: A graduate level course', written by Patterson, J.E & Magulac, M. Published in the Journal of Marital and Family Therapy in 1994 in the UK.
This is the first two paragraphs in case it is not found using Google:

HIV+ Identical twins highlight vaccine obstacles

by nycusa

UCLA Scientists Discover Immune Response To HIV Differs, Even In Identical Twins
In findings illustrating the difficulty of developing an AIDS vaccine, UCLA AIDS Institute researchers report the immune systems in two HIV-positive identical twins responded to the infection in different ways.
Detailed in the Dec. 5 issue of the peer-reviewed Journal of Virology ( the findings show that the body's defenses against the virus are random rather than genetically determined.
The researchers followed the cases of male twins who were infected shortly after their 1983 births in Los Angeles by blood transfusions administered from the same donor at the same time

Mosby Introduction to Clinical Pharmacology, 7e
Book (Mosby)
  • Used Book in Good Condition

Pharmacist Provider Status  — Pharmacy Times
In 2000, North Carolina was able to pass legislation that created a clinical pharmacist practitioner (CPP). We were able to work with the medical director for Medicare's Fiscal Intermediate to allow a CPP to bill for medical care as a provider.